Every 10-Q that Cencora, Inc. (COR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow COR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COR filings page.
Cencora, Inc. delivered higher results for the quarter and nine months ended June 30, 2026. Revenue reached $84,754,837 (in thousands) for the quarter and $249,042,769 (in thousands) for nine months, up 5.1% and 4.8% year over year. Net income attributable to Cencora rose to $763,518 (in thousands) in the quarter and $2,964,497 (in thousands) for nine months, with diluted EPS of $3.94 and $15.21, above prior-year levels.
Growth was driven mainly by U.S. Healthcare Solutions, including strong demand for GLP-1 diabetes and weight-loss therapies, and contributions from the RCA and OneOncology acquisitions. OneOncology added $820.0 million of revenue since closing. Operating cash flow was $1,687,530 (in thousands), while heavy acquisition spending produced investing outflows of $5,414,365 (in thousands) and lifted long-term debt to $11,444,086 (in thousands).
Cencora continues to manage large legal and portfolio actions. An opioid-related liability of $4.2 billion is payable over 13 years, but 2026 results include a $160.9 million litigation credit and an $86.8 million insurance recovery from a derivative settlement. The MWI Animal Health business, with $3,836,060 (in thousands) of assets held for sale, is under an FTC-reviewed merger, and a $165.7 million goodwill impairment was recorded on a divested consulting unit.
Cencora reported strong quarterly growth for the period ended March 31, 2026. Revenue reached $78.4 billion, up 3.8% year over year, driven mainly by higher volumes in U.S. Healthcare Solutions, including GLP‑1 therapies for diabetes and weight loss, and growth in European distribution.
Profitability rose sharply. Net income attributable to Cencora increased to $1.64 billion from $718 million, with diluted EPS of $8.40 versus $3.68. Results benefited from a $1.09 billion gain on remeasuring the prior OneOncology stake and continued contributions from the 2025 RCA acquisition.
The balance sheet reflects aggressive investment. Total assets grew to $81.7 billion and goodwill to $16.45 billion, largely from the $7.39 billion OneOncology acquisition. Long‑term debt rose to $12.18 billion after multiple new term loans and senior notes, while cash and cash equivalents declined to $2.18 billion. Operating cash flow was a use of $966.5 million as working capital and acquisition‑related items absorbed cash.
Cencora, Inc. reports higher results for the quarter ended December 31, 2025, with revenue of $85.9 billion, up 5.5% year over year, and net income of $566.1 million. Diluted earnings per share were $2.87, compared with $2.50 a year earlier.
Growth was driven mainly by the U.S. Healthcare Solutions segment, where revenue rose 5.0% and gross profit increased 29.5%, helped by the January 2025 acquisition of Retina Consultants of America and strong specialty and GLP‑1 product sales. International Healthcare Solutions revenue grew 9.6%, led by European distribution.
Operating income rose 7.7% to $760.4 million, despite a $249.5 million impairment tied to the U.S. Consulting Services business held for sale. Results benefited from an $86.8 million litigation credit from a derivative lawsuit settlement and a higher LIFO credit of $77.6 million. Cash used in operating activities was $2.3 billion, largely from higher inventories and receivables, while total debt was $7.9 billion. The company also highlights a $4.6 billion cash acquisition of OneOncology completed in February 2026, funded with new debt.
Q3 FY25 results: Revenue rose 8.7 % YoY to $80.7 B; gross profit +20 % to $2.9 B; operating income +29 % to $867.7 M; diluted EPS climbed 45 % to $3.52. For the nine-month period, sales reached $237.6 B (+10.6 %) and net income was $1.89 B (+25.8 %).
Cash & liquidity: Operating cash flow dropped to $0.74 B (vs $2.48 B last year) as working-capital swings outweighed earnings growth. Cash & equivalents fell to $2.23 B.
Major transaction: Closed the $5.7 B acquisition of 85 % of Retina Consultants of America, adding $1.4 B revenue and $4.8 B goodwill. Financing included $4.5 B USD notes, €1.0 B notes and a $1.5 B term loan, lifting long-term debt to $8.0 B (from $3.8 B).
Balance sheet: Total assets $74.0 B; goodwill $14.3 B. Accrued opioid-related litigation liability steady at $4.28 B. Share buy-backs of $435 M reduced outstanding shares to 193.9 M.
Segments: U.S. Healthcare Solutions delivered $72.9 B revenue (+8.5 %); International $7.79 B (+10.5 %). FX gains drove $367 M other comprehensive income.
Key watch-points: leverage expansion, potential PharmaLex goodwill impairment ($724 M), rising interest expense and continuing opioid/DEA litigation.